Recent 8-K filings for REGN

• April 29, 2026, 7:59 PM ET earnings materiality 0.80 neutral item 2.02item 9.01

  Regeneron Q1 revenue up 19% to $3.6B; non-GAAP EPS $9.47; gross margin guidance cut

  Total revenues $3,605M (+19% YoY); GAAP EPS $6.75, non-GAAP EPS $9.47.

• April 8, 2026, 7:59 PM ET earnings materiality 0.60 negative item 2.02 ◈ Earnings Releases

  Regeneron expects ~$102M IPR&D charge in Q1 2026, ~$0.81 EPS hit

  Pre-tax acquired IPR&D charge of ~$102M from milestone/up-front payments and equity securities premium.

• January 30, 2026, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Regeneron Q4 rev $3.88B (+3%), GAAP EPS $7.86; Dupixent +34% to $4.9B

  Q4 2025 total revenue $3.884B (+3% YoY); GAAP diluted EPS $7.86 (vs $8.06 Q4 2024); non-GAAP EPS $11.44 (vs $12.07).

• January 12, 2026, 6:59 PM ET other material materiality 0.20 neutral item 2.02item 7.01item 9.01

  Regeneron expects Q4 IPR&D charge of ~$19M and $60M matching donation charge

  Expects ~$19M pre-tax IPR&D charge in Q4 2025, reducing GAAP and non-GAAP diluted EPS by ~$0.14.

• October 28, 2025, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Regeneron Q3'25: Revenue $3.75B (+1%), GAAP EPS $13.62, Non-GAAP EPS $11.83; EYLEA sales down 28%

  Total revenue $3.754B (+1% YoY); GAAP EPS $13.62 (+18%), non-GAAP EPS $11.83 (-5%).

• October 6, 2025, 7:59 PM ET other material materiality 0.45 negative item 2.02

  Regeneron expects Q3 2025 pre-tax IPR&D charge of ~$83M, reducing EPS by $0.68

  Pre-tax acquired IPR&D charge of ~$83M for Q3 2025, primarily from $80M upfront to Hansoh Pharma.

• August 1, 2025, 7:59 PM ET earnings materiality 0.80 neutral item 2.02item 9.01

  Regeneron Q2 revenue $3.68B (+4%), GAAP EPS $12.81, non-GAAP EPS $12.89; Dupixent sales +22%

  Revenue $3.676B (+4% YoY); GAAP net income $1.392B, GAAP EPS $12.81 (+3%); non-GAAP EPS $12.89 (+12%).

• June 18, 2025, 7:59 PM ET other materiality 0.15 neutral item 5.07

  Regeneron shareholders elect directors, approve board declassification; two supermajority amendments fail

  Class I directors elected: Bassler (87.3M for, 18.6M against), Brown (77.0M for, 28.9M against), Schleifer (99.3M for), Yancopoulos (101.4M for).

• April 29, 2025, 7:59 PM ET earnings materiality 0.80 negative item 2.02item 9.01

  Regeneron Q1 revenue down 4%, non-GAAP EPS falls 14%; lowers gross margin guidance

  Q1 2025 revenue $3.03B (-4% YoY); GAAP EPS $7.27 (+16%), non-GAAP EPS $8.22 (-14%).

• February 4, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 8.01item 9.01

  Regeneron Q4 revenue up 10% to $3.79B; initiates $0.88 quarterly dividend, adds $3B buyback

  Q4 GAAP diluted EPS $8.06 (-21% YoY); non-GAAP diluted EPS $12.07 (+2% YoY). Full year revenue $14.20B (+8%).

• January 13, 2025, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 7.01item 9.01

  Regeneron reports 2024 prelim EYLEA sales $6B; Libtayo >$1B; Dupixent >1M patients; pipeline updates

  EYLEA HD and EYLEA aggregate U.S. net sales $6B for 2024 (+1% YoY); Q4 combined $1.5B (EYLEA HD $305M).

• October 31, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Regeneron Q3 revenue up 11% to $3.72B; GAAP EPS $11.54; Dupixent sales +23%

  Revenue $3.72B (+11% YoY); GAAP net income $1.34B, diluted EPS $11.54 (up 30%).

• October 7, 2024, 7:59 PM ET other material materiality 0.55 negative item 2.02

  Regeneron expects $56M pre-tax IPR&D charge in Q3 2024, reducing EPS by $0.43

  Preliminary $56M pre-tax acquired IPR&D charge expected for Q3 2024 from milestone/up-front payments.

• August 1, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Regeneron Q2 revenue up 12% to $3.55B, EPS beats; EU approves Dupixent for COPD

  Total revenue $3.55B (+12% YoY); GAAP diluted EPS $12.41 (+46%); non-GAAP diluted EPS $11.56 (+13%).

• July 8, 2024, 7:59 PM ET earnings materiality 0.55 negative item 2.02

  Regeneron expects $24M IPR&D charge in Q2 2024, ~$0.18 EPS hit

  Estimated pre-tax acquired IPR&D charge of ~$24 million for Q2 2024.

• June 20, 2024, 7:59 PM ET other materiality 0.15 neutral item 5.07

  Regeneron shareholders elect directors, approve executive compensation at 2024 annual meeting

  Class III directors elected: N.A. Coles, K. Guarini, A.F. Ryan, G.L. Sing; Class II director D.P. Schenkein elected.

• May 2, 2024, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01 ◈ Earnings Releases

  Regeneron Q1 revenue down 1% to $3.15B; Non-GAAP EPS $9.55; new $3B buyback

  GAAP net income $722M ($6.27 diluted EPS) vs $818M ($7.17) YoY; Non-GAAP net income $1,116M ($9.55).

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.75 · Most common event earnings

4 positive 5 negative 8 neutral

source · REGN on sec.gov